Yourgene Health
Yourgene Health plc - Home.
| Date | Investors | Amount | Round |
|---|---|---|---|
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
* | £16.7m Valuation: £16.7m 3.5x EV/EBITDA | Acquisition | |
| Total Funding | 000k | ||
| EUR | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | - | 75 % | 43 % | 100 % | - | 122 % | - |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | (200 %) | (114 %) | (40 %) | (5 %) | (25 %) | 8 % | - |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | 50 % | 71 % | 70 % | 50 % | 50 % | (5 %) | - |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | - | - | 3 % | - | 2 % | 5 % | - |
Source: Company filings or news article
Yourgene Health plc, established in 2000, operates as an international molecular diagnostic group, concentrating on the development and commercialization of genetic products and services. The company was formerly known as Premaitha Health plc before rebranding to Yourgene Health plc in February 2019. It provides a range of solutions to clinical, research, and pharmaceutical organizations, with a focus on reproductive health, precision medicine, and infectious diseases.
The company's offerings are built around key technologies in NGS, PCR, and bioinformatics. A significant part of its portfolio is dedicated to non-invasive prenatal testing (NIPT), with products like the IONA® test, which is a CE-marked in vitro diagnostic (IVD) product for screening for Down's syndrome and other genetic conditions. This allows clinical laboratories to run the tests in-house, providing them with greater control and faster turnaround times. The business model involves the sale of these testing kits, instruments, and associated software and services to laboratories and healthcare providers globally.
Beyond reproductive health, Yourgene Health has expanded its portfolio to include oncology and infectious diseases. For instance, the company offers solutions for Duchenne Muscular Dystrophy (DMD) screening and has developed PCR-based tests for COVID-19, such as the Clarigene® SARS-CoV-2 test. The company's customer base includes hospital and private laboratories, as well as pharmaceutical and contract research organizations. Geographically, it has a commercial footprint across the UK, Europe, the MEA region, and Asia.
In a significant corporate development, Yourgene Health was acquired by Novacyt S.A. in a transaction completed in September 2023. This acquisition integrated Yourgene into Novacyt's diagnostics business, aiming to create a more comprehensive entity in the diagnostics space by combining Yourgene's genomic testing solutions with Novacyt's portfolio.
Keywords: molecular diagnostics, genetic testing, non-invasive prenatal testing, NIPT, reproductive health, precision medicine, oncology diagnostics, infectious disease testing, PCR, genomic services
Tech stack
Investments by Yourgene Health
Edit